Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Why Herceptin isn't perfect

As with many drugs, fatal adverse events have been detected during postmarketing surveillance of Genentech Inc.'s Herceptin trastuzumab anti-HER2 monoclonal antibody to treat breast cancer. While such side effects were not seen in the company's clinical trials, DNA does not believe that the

Read the full 435 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE